SATURDAY, Sept. 28, 2002 (HealthDayNews) -- Beth Israel's Cancer Center in New York City is recruiting patients as part of a worldwide Phase III clinical trial of a drug to treat metastatic prostate cancer.
The trial will evaluate the drug atrasentan in the treatment of hormone-refractory prostate cancer. People with advanced prostate cancer who are no longer responding to hormone therapy may be eligible to participate.
Metastatic prostate cancer is cancer that's spread beyond the prostate gland.
"Despite the many advances in the treatment of prostate cancer over the last several years, the treatment of hormone refractory prostate cancer remains difficult. This clinical trial allows us to examine a new option to determine its potential benefit for individuals with hormone refractory prostate cancer," says the trial's lead investigator Dr. Joseph Wagner, physician-in-charge of Urologic Oncology at Beth Israel.
Patient eligibility requirements for this trial are:
- A diagnosis of prostate cancer.
- A rising PSA while on hormone therapy or following castration.
- No evidence of distant metastatic disease on CT scan.
- No clinically significant disease such as congestive heart failure or pulmonary disease.
The drug atrasentan is an investigational endothelin receptor blocker. It acts by blocking a protein that causes prostate cells to grow.
More information
Click here to learn more about atrasentan.
